Can brain scans and eye tests predict Alzheimer's years before symptoms?
NCT ID NCT05806697
First seen Jul 07, 2026 · Last updated Jul 08, 2026 · Updated 1 time
Summary
This study follows older adults (ages 70-95) who have memory concerns but no dementia, tracking them for up to 5 years to see who develops Alzheimer's. Researchers use brain scans, EEG, eye movement tests, and memory assessments to spot early warning signs. The goal is to better understand how Alzheimer's unfolds in its earliest, pre-symptomatic stage.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- What this could lead to
- If successful, this could help identify early markers of Alzheimer's disease before symptoms worsen, enabling earlier intervention.
- What could go wrong
- This is an observational study, not a treatment trial, so it won't directly improve health. It may not find reliable predictors, and results may not apply to broader populations.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 240 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Apr 2023
- Expected to finish
-
Oct 2030
An estimate. End dates often move.
- Lead sponsor
-
A government agency
The lead sponsor is a government body.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
70 to 95 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Subjects that previously participated in the INSIGHT cohort * Aged 70 to 95 years old * Having signed an informed consent * Willing to and able undergo a baseline PET amyloid imaging * Affiliating to the French health-care system * Having an identified informant who has sufficient contact with the participant and has to be able to provide accurate information, at least by phone, about the participants' cognitive and functional abilities. Exclusion Criteria: * Clinical Dementia Rating ≥1 at screening/baseline visit only * Fulfilling research diagnostic criteria for any type of dementia-related disorder at screening visit (clinical AD, Dementia with Lewy Bodies \[DLB\], fronto-temporal dementia \[FTD\], vascular dementia, chronic traumatic encephalopathy \[CTE\], Limbic-predominant Age-related TDP-43 Encephalopathy \[LATE\], Primary age-related tauopathy \[PART) * Presence of any medical condition associated with a long-term risk of cognitive impairment or dementia including Parkinson's disease, brain tumor, subdural hematoma, vascular malformations, territorial stroke (excluding smaller watershed strokes), chronic hydrocephalus, traumatic brain injury with neurological sequelae, active alcohol/drug abuse, major depressive disorder, schizophrenia and bipolar disorder * Current serious or unstable illnesses (including cardiovascular, hepatic, renal, gastroenterologic, respiratory, endocrinologic or hematologic disease) that might make the subject's participation in an investigational trial unsafe * Any contraindications for MRI/ PET scan procedure (claustrophobia, ferromagnetic object in the body), to FDG or to 18F-Florbetapir (Amyvid®). * Hypersensitivity to the active substance or to any of the excipients of 18F-Florbetapir (Amyvid®). * Participation in any clinical trial of an investigational product in the last 30 days before the screening (during all study duration co-inclusion in other clinical trial of an investigational product or observational research \[biomarker cohort e.g.\] will be possible but the information would need to be recorded). * Unable to comply with protocol requirements in the opinion of the investigator * Being under guardianship (safeguard of justice, curatorship or guardianship) * Residence in skilled nursing facility, including nursing homes (EHPAD).
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Alzheimer disease are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Hôpital Pitié Salpêtrière
RECRUITINGParis, Île-de-France Region, 75013, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Glutathione, brain metabolism and inflammation in Alzheimer's disease
- Can an experimental infusion reach the brain to fight Alzheimer's?
- A new roadmap to predict Alzheimer's before memory fails
- Can a 500-Person study unlock Alzheimer's early signs?
- AI hunts for early clues to Parkinson's and Alzheimer's progression
- Can a daily supplement slow early Alzheimer's memory decline?